Small Molecules from Nature Targeting G-Protein Coupled Cannabinoid Receptors: Potential Leads for Drug Discovery and Development

Table 2

The cannabinoid receptor affinity, potency, and activity of lead molecules.

Compound	CB receptor mediated effect	CB receptor affinity/potency	References
γ-Sanshool	Diabetes	CB2 agonist	Dossou et al. 2013 [106]
4′-O-Methylhonokiol	Alzheimer’s diseases	CB2 agonist	Gertsch and Anavi-Goffer 2012 [87]; Schuehly et al. 2011 [85]
Yangonin	Anxiety	CB1 receptor antagonist	Ligresti et al. 2012 [112]
Amyrin	Neuropathic pain	CB1/CB2 agonist, MAGL inhibitor	Simão da Silva et al. 2011 [33]
Betulinic acid	Cancer	CB1 antagonist/CB2 agonist	Liu et al. 2012 [38]
β-Caryophyllene	Ulcerative colitis; Alzheimer’s diseases; Insulin resistance; Alcohol addiction; Anxiety; Depression; Nephrotoxicity; Cerebral ischemia	CB2 agonist	Bento et al. 2011 [40]; Horváth et al. 2012 [47]; Al Mansouri et al. 2014 [41]; Bahi et al. 2014 [49]; Choi et al. 2013 [43]; Klauke et al. 2014 [50]; Suijun et al. 2014 [44]; Guo et al. 2014 [42]; Gertsch et al. 2008 [18]
Celastrol	Neuropathic pain	CB2 agonist	Yang et al. 2014 [55]
Chelerythrine	Neuropathic pain; Neuroblastoma	CB1 antagonist	Lim et al. 2003 [57]
Curcumin	Neuroprotective; liver fibrosis	CB1 antagonist/CB2 agonist	Hassanzadeh and Hassanzadeh, 2012 [64]
Euphol	Neuropathic pain	CB1/CB2 agonist, MAGL inhibitor	Dutra et al. 2012 [71]
18β-Glycyrrhetinic acid	Obesity	CB1 antagonist	Park et al. 2014 [73]
Pristimerin	Pain & inflammation	MAGL inhibitor	Chicca et al. 2012 [34]
Salvinorin A	Anxiety; Depression; Neuropathic pain; Ulcerative colitis	CB1 agonist, FAAH inhibitor	Fichna et al. 2012 [102]; Aviello et al. 2011 [100]; Capasso et al. 2008 [98]; Braida et al. 2009 [95]; Braida et al. 2007 [99]
Malyngamide B	Inflammation	CB1/CB2 agonist	Montaser et al. 2012 [82]
Rutin	Depression	CB1 agonist	Su et al. 2014 [83]
Serinolamide B	Inflammation; Cancer	CB1 and CB2 receptors action	Montaser et al. 2012 [82]